Roy Baynes Buys Shares of Travere Therapeutics

Roy Baynes, an insider at Travere Therapeutics, Inc. (NasdaqGM: TVTX), purchased 4,500 shares on June 12, 2026. The transaction was valued at $96,210, with an average share price of $21.38.

Insider Buying and Selling at Travere Therapeutics, Inc.

On June 12, 2026, Roy Baynes acquired 4,500 shares of Travere Therapeutics at an average price of $21.38, totaling $96,210. This purchase was not part of a pre-planned trading agreement. Additionally, Timothy Coughlin, another insider, bought 10,000 shares at $26.52 each and sold the same amount at $50.07 under a planned sale.

Other Institutional Activity in Travere Therapeutics

Several institutional investors have adjusted their positions in Travere Therapeutics. Janus Henderson Group PLC increased its holdings by 908,420 shares, reaching a total of 11,419,586 shares, valued at approximately $339.2 million. FMR LLC also boosted its stake by 1,350,104 shares, ending with 10,967,967 shares worth about $325.9 million. BlackRock, Inc. trimmed its position by 77,319 shares, resulting in 7,792,033 shares valued at $231.5 million. Meanwhile, State Street Corp added 203,322 shares, bringing its total to 4,959,988 shares, valued at $147.4 million.

Travere Therapeutics Stock Snapshot

Shares of Travere Therapeutics (NasdaqGM: TVTX) were trading near $53.80. The company boasts a market capitalization of around $5 billion and a forward P/E ratio of 11.08. The stock has a 52-week range between $13.88 and $53.88, with a 50-day moving average of $42.45 and a 200-day moving average of $33.07. Travere has a current ratio of 3.13 and a debt-to-equity ratio of 331.88.

Recent Earnings

Travere Therapeutics reported revenue of $536.2 million, reflecting a growth rate of 55.6%. Despite this, the company has a negative net margin of 4% and a return on equity of -69.38%. The next earnings report is expected on August 6, 2026.

Analysts Set New Price Targets

On June 15, 2026, Citigroup maintained its buy rating on Travere Therapeutics, setting a price target of $70. Wells Fargo also maintained a buy rating with a $65 target on June 12. The consensus among 14 analysts is a strong buy, with an average price target of $56.14.

About Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing therapies for rare kidney and metabolic diseases. Its key products include FILSPARI, a treatment for IgA Nephropathy, and Thiola, used for cystinuria. The company, led by CEO Dr. Eric M. Dube, employs 497 people.

Bottom Line

The recent insider purchase by Roy Baynes highlights confidence in Travere Therapeutics. The company's stock is backed by strong institutional activity and favorable analyst ratings. Investors should note that this information is based on past transactions and may not reflect current positions.